These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 36960067)

  • 1. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
    Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
    Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model.
    Golchin S; Alimohammadi R; Rostami Nejad M; Jalali SA
    J Cell Physiol; 2019 Nov; 234(11):19866-19874. PubMed ID: 30941773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model.
    Xin M; Lin D; Yan N; Li H; Li J; Huang Z
    Anticancer Drugs; 2022 Feb; 33(2):117-123. PubMed ID: 34561996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
    Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
    BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8
    Xia W; Zhang S; Duan H; Wang C; Qian S; Shen H
    Med Oncol; 2022 Jan; 39(3):37. PubMed ID: 35059863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
    Chen S; Zhang S; Fan W; Sun W; Liu B; Liu J; Guo Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):210-216. PubMed ID: 38501405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
    Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
    Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
    Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
    Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of radiotherapy and Anlotinib enhances benefit from immunotherapy to liver metastasis and abscopal tumor from lung cancer.
    Jiang Y; Qiao S; Li L; Zhu X
    Int Immunopharmacol; 2024 Feb; 128():111441. PubMed ID: 38171056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
    Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
    Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.